Download PDF
Semin Vasc Med 2001; 01(1): 081-088
DOI: 10.1055/s-2001-14544
Copyright © 2001 by Thieme Medical Publishers, Inc., 333 Seventh Avenue, New York, NY 10001, USA. Tel.: +1(212) 584-4662

Venous Thromboembolic Disease: Risk Factors and Laboratory Investigation

Martine Alhenc-Gelas1 , Martine Aiach1 , Philippe de Moerloose2
  • 1Service d'Hématologie Biologique A, Hôpital Européen Georges Pompidou, Paris, France
  • 2Haemostasis Unit, University Hospital, Geneva, Switzerland
Further Information

Publication History

Publication Date:
31 December 2001 (online)

    Permissions and Reprints

ABSTRACT

The etiology of venous thromboembolic disease has been the subject of several recent discoveries, particularly on genetic predisposing factors. The laboratory investigation that may help to evaluate the risk for individual patients includes the measurements of coagulation inhibitors (antithrombin, protein C, and protein S) in plasma assays, the search for the factor V Leiden mutation by the plasma activated protein C resistance test (always to be confirmed by DNA analysis when abnormal), and the search for the prothrombin gene mutation by DNA analysis. Among acquired abnormalities, the most frequently involved are phospholipid-dependent autoantibodies associated or not with a subset of antibodies having an anticoagulant effect in vitro (lupus anticoagulant). Other coagulation abnormalities such as increased FVIII, FIX, or FXI levels or hyperhomocysteinemia have been suggested to be risk factors for thrombosis, although additional studies are required to definitively assess their role.

KEYWORD

Thrombophilia - deep vein thrombosis - laboratory investigation

REFERENCES

  • 1 Rosendaal F R. Venous thrombosis: a multicausal disease.  Lancet . 1993;  353 1167-1173
    PubMedGoogle Scholar
  • 2 Olds R J, Fitches A, Geary C P. The multigenic basis for venous thrombosis.  Br J Haematol . 2000;  109 508-511
    CrossrefPubMedGoogle Scholar
  • 3 Lane D A, Grant P J. Role of hemostatic gene polymorphisms in venous and arterial thrombotic disease.  Blood . 2000;  95 1517-1532
    PubMedGoogle Scholar
  • 4 Lane D A, Mannucci P M, Bauer K A. Inherited thrombophilia: part 1.  Thromb Haemost . 1996;  76 651-662
    PubMedGoogle Scholar
  • 5 Egeberg O. Inherited antithrombin deficiency causing thrombophilia.  Thromb Diath Haemorrh . 1965;  13 516-530
    PubMedGoogle Scholar
  • 6 Lane D A, Olds R J, Boisclair M. Antithrombin mutation database: first update. For the thrombin and its inhibitors subcommittee of the international society on thrombosis and haemostasis.  Thromb Haemost . 1993;  70 361-369
    PubMedGoogle Scholar
  • 7 Reitsma P H, Bernardi F, Doig R G. Protein C deficiency: a database of mutations, 1995 update. On behalf of the subcommittee on plasma coagulation inhibitors of the scientific and standardization committee of the ISTH.  Thromb Haemost . 1995;  73 876-889
    PubMedGoogle Scholar
  • 8 Gandrille S, Borgel D, Ireland H, et al. for the plasma coagulation inhibitors subcommittee of the scientific and standardization committee of the international society on thrombosis and haemostasis. Protein S deficiency: a database of mutations.  Thromb Haemost . 1997;  77 1201-1214
    PubMedGoogle Scholar
  • 9 Dahlbäck B, Carlsson M, Svensson P. Familial thrombophilia due to a previously unrecognized mechanism characterized by poor anticoagulant response to activated protein C: prediction of a cofactor to activated protein C.  Proc Natl Acad Sci USA . 1993;  90 1004-1008
    CrossrefPubMedGoogle Scholar
  • 10 Bertina R M, Koeleman B P, Koster T. Mutation in blood coagulation factor V associated with resistance to activated protein C.  Nature . 1994;  369 64-67
    CrossrefPubMedGoogle Scholar
  • 11 Bernardi F, Faioni E M, Castoldi E. A factor V genetic component differing from factor V R506Q contributes to the activated protein C resistance.  Blood . 1997;  90 1552-1557
    PubMedGoogle Scholar
  • 12 Poort R S, Rosendaal F R, Reitsma P H, Bertina R M. A common genetic variation in the 3′ untranslated region of the prothrombin gene is associated with elevated plasma prothrombin levels and an increase in venous thrombosis.  Blood . 1996;  88 3698-3703
    CrossrefPubMedGoogle Scholar
  • 13 Petri M. Epidemiology of the antiphospholipid antibody syndrome.  J Autoimmunity . 2000;  15 145-151
    CrossrefPubMedGoogle Scholar
  • 14 Koster T, Blann A D, Briet E, Vandenbroucke J P, Rosendaal F R. Role of clotting factor VIII in effect of von Willebrand factor on occurrence of deep-vein thrombosis.  Lancet . 1995;  345 152-155
    CrossrefPubMedGoogle Scholar
  • 15 Van Hylckama Vlieg A, Van der Linden K I, Bertina R M, Rosendaal F R. High levels of factor IX increase the risk of venous thrombosis.  Blood . 2000;  95 3678-3682
    PubMedGoogle Scholar
  • 16 Meijers J CM, Tekelenburg W LH, Bouma B N. High levels of coagulation factor XI as a risk factor for venous thrombosis.  N Engl J Med . 2000;  342 696-701
    CrossrefPubMedGoogle Scholar
  • 17 Cattaneo M. Hyperhomocysteinemia, atherosclerosis and thrombosis.  Thromb Haemost . 1999;  81 165-176
    PubMedGoogle Scholar
  • 18 Rees D C, Cox M, Clegg J B. World distribution of factor V Leiden.  Lancet . 1995;  346 1133-1134
    CrossrefPubMedGoogle Scholar
  • 19 Rosendaal F R, Doggen C JM, Zivelin A. Geographic distribution of the 20210G to A prothrombin variant.  Thromb Haemost . 1998;  79 706-708
    Article in Thieme ConnectPubMedGoogle Scholar
  • 20 Lane D, Mannucci P M, Bauer K A. Inherited thrombophilia: part 2.  Thromb Haemost . 1996;  76 824-834
    PubMedGoogle Scholar
  • 21 Salomon O, Steinberg D M, Zivelin A. Single and combined prothrombotic factors in patients with idiopathic venous thromboembolism. Prevalence and risk assessment.  Arterioscler Thromb Vasc Biol . 1999;  19 511-518
    PubMedGoogle Scholar
  • 22 Speroff L. Oral contraceptives and arterial and venous thrombosis: a clinician's formulation.  Am J Obstet Gynecol . 1998;  179 S25-S36
    PubMedGoogle Scholar
  • 23 Martinoli J L, Stocker K. Fast functional protein C assay using Protac, a novel protein C activator.  Thromb Res . 1986;  43 253-264
    CrossrefPubMedGoogle Scholar
  • 24 Allaart C F, Poort S R, Rosendaal F R. Increased risk of venous thrombosis in carriers of hereditary protein C deficiency defect.  Lancet . 1993;  341 134-138
    CrossrefPubMedGoogle Scholar
  • 25 Faioni E M, Franchi F, Asti D. Resistance to activated protein C in nine thrombophilic families: interference in a protein S functional assay.  Thromb Haemost . 1993;  71 1067-1071
    PubMedGoogle Scholar
  • 26 Dahlbäck B. Resistance to activated protein C, the Arg506 to Gln mutation in the factor V gene and venous thrombosis. Functional tests and DNA-based assays, pros and cons.  Thromb Haemost . 1995;  73 739-742
    PubMedGoogle Scholar
  • 27 Lutz C T. DNA-based assay formats for detecting thrombosis factor V genotypes.  J Clinical Ligand Assay . 1997;  20 235-244
    PubMedGoogle Scholar
  • 28 Gomez A, Van der Poel SC A M P, Jansen J H. Rapid simultaneous screening of factor V Leiden and G20210A prothrombin variant by multiplex polymerase chain reaction on whole blood.  Blood . 1998;  6 2208-2211
    PubMedGoogle Scholar
  • 29 Brandt J T, Triplett D A, Alving B, Scharrer I. Criteria for the diagnosis of lupus anticoagulants: an update.  Thromb Haemost . 1995;  74 1185-1190
    Article in Thieme ConnectPubMedGoogle Scholar
  • 30 Carreras L O, Forastiero R R, Martinuzzo M E. Which are the best biological markers of the antiphospholipid syndrome?.  J Autoimmunity . 2000;  15 163-172
    CrossrefPubMedGoogle Scholar
      >